bioRxivNeurosciencePreprint
DJ-1 mediates regulation of metabolism and immune response in Parkinsons disease astrocytes and Glioblastoma cells
Pauline MenckeiD, Jochen OhnmachtiD, Félicia JeannelleiD, Adrien J Ries, Mónica Miranda de la MazaiD, Mathilde M. Ullrich, François MassartiD, Patrycja MulicaiD, Katja BadanjakiD, Zoé HanssiD, Arkadiusz Rybicki, Paul M. A. AntonyiD, Sylvie DelcambreiD, Giuseppe ArenaiD, Gérald Cruciani, Javier JarazoiD, Floriane GavottoiD, Christian JägeriD, Anouk EweniD, Maria Pires PachecoiD, Dirk BrenneriD, Jens Christian SchwamborniD, Thomas SauteriD, Lasse SinkkoneniD, Gunnar A. G. DittmariD, , Ibrahim BoussaadiD
- Citations
- 0
Abstract
An inverse correlation for the expression of Parkinsons disease (PD)- and cancer-associated genes has been previously reported. Genes that are upregulated in cancer are frequently downregulated in PD and vice versa. PARK7, encoding DJ-1, was initially identified as an oncogene, but loss of DJ-1 causes early-onset PD. However, it remains elusive how differential DJ-1 levels contribute to opposite cell fates in cancer and PD. Here, we demonstrate specific effects of differential DJ-1 protein levels on the energy metabolism and cell growth in patient-derived cellular models of PD and glioblastoma (GBM) cell lines. Impaired energy metabolism was associated with an increased immune response upon IL-1{beta} stimulation and increased apoptosis and decreased cell growth in models of PD, whereas in GBM cells increased metabolic activity translated into a reduced immune response and increased cell growth. Furthermore, we found decreased glutathione (GSH) synthesis and therefore increased levels of reactive oxygen species (ROS) and oxidized glutathione (GSSG) in models of DJ-1 deficiency and decreased ROS levels in GBM cell lines. Thus, the mechanism by which DJ-1 modulates these phenotypes is the same in both diseases. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=84 SRC="FIGDIR/small/621212v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@4eccb4org.highwire.dtl.DTLVardef@161669corg.highwire.dtl.DTLVardef@197bfc3org.highwire.dtl.DTLVardef@1aecb36_HPS_FORMAT_FIGEXP M_FIG C_FIG DJ-1 levels modulate GSSG/GSH ratio and ROS levels, which results in divergent effects on cell growth and immune response in DJ-1-dependent glial pathologies in glioblastoma and PD. In models of PD, DJ-1 level dependent phenotypes can be rescued by antioxidant treatment that reduces the GSSG/GSH ratio and ROS levels.
- organism: human
- assay: bulk RNA-seq
- assay: metabolomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Enhanced activity of glycolytic enzymes in Drosophila and human cell models of Parkinson's disease based on DJ-1 deficiency
Cristina Solana‐Manrique, F. Sanz, … Nuria Paricio·Free Radical Biology and MedicinePeer-reviewed·Jul 26, 2020
- Loss of the Parkinson's disease-associated protein DJ-1 impacts dopamine metabolism in astrocytes
Annika Wagener, Naiyareen Fareeza Mayeen, … Lena F. Burbulla·bioRxiv·Nov 2, 2025
- Products of the Parkinson’s-disease related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survival
Yusuke Toyoda, Cihan Erkut, … Teymuras V. Kurzchalia·bioRxiv·Jul 4, 2014
- Parkinson disease-associated protein DJ-1 regulates the autophagic-lysosomal pathway through ROS-dependent modulation of the AMPK/mTORC1 axis.
Francesco Agostini, Federica De Lazzari, … Marco Bisaglia·bioRxiv·Apr 13, 2026
- DJ-1 (Park7) affects the gut microbiome, metabolites, and development of Innate Lymphoid Cells (ILCs)
Y. Singh, C. Trautwein, … O. Riess·bioRxiv·Sep 19, 2019
- Myeloid PINK1 represses mtDNA release and immune signaling that impacts neuronal pathology in patient-derived idiopathic PD models
Sherilyn Junelle Recinto, Adam MacDonald, … Jo Anne Stratton·bioRxiv·Jan 8, 2026